ArticleInflammation research : official journal of the European Histamine Research Society ... [et al.]2026
Re-evaluation of the prognosis of patients with IgA nephropathy and mild proteinuria: a longitudinal study with unexpected results.
Article in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundIgA nephropathy (IgAN) is the most common primary glomerulonephritis worldwide and a major cause of chronic kidney disease. Mild proteinuria (< 0.5 g/24 h) is generally considered to indicate a favorable prognosis in IgAN. This study aimed to explore the clinicopathological features and prognostic factors of such patients.
methodWe performed a retrospective analysis of IgAN patients who had renal biopsies at our hospital from 2008 to 2023. We included patients with 24-hour proteinuria < 0.5 g, age ≥ 15 years, and follow-up ≥ 12 months. Risk factors were assessed using logistic regression and Cox proportional hazards models.
resultsOver a mean follow-up of 90.75months, 27 patients(10.19%) experienced endpoint events. The overall eGFR slope was - 2.07mL/min/1.73 m
conclusionsOur study challenges the assumption that IgAN patients with mild proteinuria have a favorable prognosis. Over 90.75 months, 10.19% of patients experienced endpoint events, with an eGFR decline of 2.07 mL/min/1.73 m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.